Lowest-Rated StocksLowest-RatedNASDAQ:RAPT RAPT Therapeutics (RAPT) Stock Price, News & Analysis $1.83 -0.10 (-5.18%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.80▼$1.9450-Day Range$1.83▼$3.7552-Week Range$1.80▼$27.35Volume248,984 shsAverage Volume822,898 shsMarket Capitalization$63.87 millionP/E RatioN/ADividend YieldN/APrice Target$21.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get RAPT Therapeutics alerts: Email Address RAPT Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.18 Rating ScoreUpside/Downside1,078.8% Upside$21.57 Price TargetShort InterestBearish9.94% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.67Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.73) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector259th out of 910 stocksPharmaceutical Preparations Industry108th out of 426 stocks 3.1 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageRAPT Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about RAPT Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.94% of the outstanding shares of RAPT Therapeutics have been sold short.Short Interest Ratio / Days to CoverRAPT Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in RAPT Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRAPT Therapeutics has received a 42.81% net impact score from Upright. Rapt Therapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for RAPT Therapeutics is -0.81. Previous Next 2.0 News and Social Media Coverage News SentimentRAPT Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RAPT Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of RAPT Therapeutics is held by insiders.Percentage Held by Institutions99.09% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RAPT Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to grow in the coming year, from ($2.73) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about RAPT Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About RAPT Therapeutics Stock (NASDAQ:RAPT)RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyRead More RAPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAPT Stock News HeadlinesSeptember 1, 2024 | americanbankingnews.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from AnalystsAugust 30, 2024 | finance.yahoo.comRAPT Therapeutics, Inc. (RAPT) Stock Price, News, Quote & History - Yahoo FinanceSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 20, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)August 12, 2024 | markets.businessinsider.comPrelude Therapeutics Inc Q2 Loss Misses EstimatesAugust 9, 2024 | markets.businessinsider.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024August 8, 2024 | finance.yahoo.comRAPT Therapeutics Reports Second Quarter 2024 Financial ResultsMay 20, 2024 | seekingalpha.comRAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric OpportunitySeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. May 14, 2024 | msn.comWolfe downgrades RAPT, but still sees "immense" upside potentialMay 12, 2024 | finance.yahoo.comHere's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn SituationMay 11, 2024 | msn.comRAPT terminates Phase II trials for lead candidate following clinical holdMay 11, 2024 | msn.comBarclays Downgrades RAPT Therapeutics (RAPT)May 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial OutlookMay 10, 2024 | msn.comRAPT falls for second day as Guggenheim, Barclays downgrade stockMay 10, 2024 | finance.yahoo.comRAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 9, 2024 | morningstar.comRAPT Therapeutics Shares Hit 52-Week Low After Trials ClosedMay 9, 2024 | finance.yahoo.comRAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon TrialsSee More Headlines Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPT CUSIPN/A CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees80Year Founded2015Price Target and Rating Average Stock Price Target$21.57 High Stock Price Target$41.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,078.8%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.04% Return on Assets-73.43% Debt Debt-to-Equity RatioN/A Current Ratio8.14 Quick Ratio8.14 Sales & Book Value Annual Sales$1.53 million Price / Sales41.75 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book0.43Miscellaneous Outstanding Shares34,903,000Free Float32,599,000Market Cap$63.87 million OptionableOptionable Beta0.33 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Brian Russell Wong M.D. (Age 52)Ph.D., CEO, President & Director Comp: $861.24kMr. Rodney K. B. Young (Age 61)CFO, Principal Accounting Officer & Secretary Comp: $616.56kDr. William Ho M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $620.32kSteve Young Ph.D.Vice President of TechnologyDr. Dirk G. Brockstedt Ph.D. (Age 55)Chief Scientific Officer Comp: $490.25kMr. Michael ListgartenGeneral CounselMs. Gwen R. Carscadden (Age 63)Chief Human Resources Officer Dr. Paul Kassner (Age 57)Senior Vice President of Quantitative & Computational Biology Dr. David Wustrow (Age 65)Senior Vice President of Drug Discovery & Preclinical Development Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDCartesian TherapeuticsNASDAQ:RNACPoseida TherapeuticsNASDAQ:PSTXZura BioNASDAQ:ZURAuniQureNASDAQ:QUREView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 706,900 shares on 8/19/2024Ownership: 2.027%Algert Global LLCSold 6,405 shares on 8/16/2024Ownership: 0.136%Affinity Asset Advisors LLCSold 32,100 shares on 8/15/2024Ownership: 0.000%AQR Capital Management LLCBought 88,373 shares on 8/15/2024Ownership: 0.253%The Manufacturers Life Insurance Company Sold 10,864 shares on 8/15/2024Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions RAPT Stock Analysis - Frequently Asked Questions How have RAPT shares performed this year? RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT shares have decreased by 92.6% and is now trading at $1.83. View the best growth stocks for 2024 here. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced its earnings results on Thursday, August, 8th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.03. What is Brian Wong's approval rating as RAPT Therapeutics' CEO? 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did RAPT Therapeutics IPO? RAPT Therapeutics (RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO. Who are RAPT Therapeutics' major shareholders? Top institutional shareholders of RAPT Therapeutics include Federated Hermes Inc. (2.28%), Point72 Asset Management L.P. (2.03%), Affinity Asset Advisors LLC and Acadian Asset Management LLC (1.34%). Insiders that own company stock include Group Ii Lp Column, Dirk G Brockstedt, William Ho, Wendye Robbins and Rodney Kb Young. View institutional ownership trends. How do I buy shares of RAPT Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH) and Inovio Pharmaceuticals (INO). This page (NASDAQ:RAPT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts